These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MiR-508-5p is a prognostic marker and inhibits cell proliferation and migration in glioma.
    Author: Liu YH, Li B, Meng FG, Qiu L.
    Journal: Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):76-81. PubMed ID: 28121353.
    Abstract:
    OBJECTIVE: Increasing evidence has informed that dysregulation of microRNAs (miRNAs) may contribute to carcinogenesis in human. The aim of the present study was to determine the role of miR-508-5p in glioma. PATIENTS AND METHODS: Quantitative real-time PCR was performed to detect the expression levels of miR-508-5p in glioma and normal control tissues. In vitro, migration assays and a wound-healing assay were performed to determine the effects of miR-508-5p. Associations between miR-508-5p expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan-Meier. Univariate and multivariate analyses were performed to estimate the effects of the expression of miR-508-5p on survival. RESULTS: The expression of miR-508-5p was downregulated in glioma tissues and cell lines. Low miR-508-5p expression was related to WHO grade (p = 0.005) and KPS score (p = 0.013). Moreover, Kaplan-Meier survival analysis showed that low miR-508-5p expression was significantly associated with short overall survival (p = 0.0059). Furthermore, multivariate analysis revealed that miR-508-5p was an independent prognostic factor for the overall survival in glioma (p = 0.002). Finally, forced expression of miR-508-5p could inhibit glioma cell growth and metastasis in vitro. CONCLUSIONS: Taken together, our study suggested that miR-508-5p may be served as a novel prognostic factor and may lead to new treatment strategies for glioma.
    [Abstract] [Full Text] [Related] [New Search]